English

Claus Bræstrup resigns as President and CEO of Lundbeck

Report this content 

                        
Claus Bræstrup today resigned from his position as President and CEO
of H. Lundbeck A/S and will step down immediately. Until a
replacement has been found, Per Wold-Olsen, Chairman of the
Supervisory Board, will act as executive chairman. The company's
strategy of being a research-based company focusing on diseases of
the central nervous system (CNS) will remain unchanged."Of course, it is sad to say goodbye to a company that I have enjoyed
working for during the past ten years, first as head of research and
later as CEO," says Claus Bræstrup. He continues: "We recently
announced the best ever financial performance in Lundbeck's history,
we expect continuing growth for 2008 and have a sound foundation for
ensuring successful operations for Lundbeck in the long term.""It is regrettable that Claus Bræstrup has decided to resign from his
position sooner than we had expected. Claus Bræstrup has been
instrumental in building Lundbeck's research and development
activities, the proof of which we are currently witnessing in the
form of the largest and broadest pipeline of pharmaceutical
candidates in development in Lundbeck's history. Also, he was at the
helm of Lundbeck when the company successfully switched more than 80%
of its revenue from one product to other new pharmaceuticals. On
behalf of the Supervisory Board, I would like to thank Claus Bræstrup
for his efforts at Lundbeck," says Per Wold-Olsen, Chairman of the
Supervisory Board. "Some time ago, Claus Bræstrup disclosed his
considerations to retire after Lundbeck had announced its financial
results for 2007. The process of identifying in-house and external
candidates is therefore well underway, and we expect to announce the
name of Lundbeck's new president and CEO within the next couple of
months."

Lundbeck contacts


Investors:                 Media:

Jacob Tolstrup             Anders Schroll
Director                   Head of Communication
+45 36 43 30 79            +45 36 43 20 81

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


Stock Exchange Release No 327 - 5 March 2008

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2007,
the company's revenue was DKK 11 billion (approximately EUR 1.5
billion or USD 2.0 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com




                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links